Lexli International, Inc. – Trademark Portfolio
Entity Type: 03
Lexli International, Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include LEXLI and ALOEGLYC. The owner is based in Fargo, ND.
3270 20th Street S.
Fargo, ND 58104
Showing of trademarks Trademarks
Trademark Classifications
Lexli International, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Lexli International, Inc. have?
Lexli International, Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 cancelled.
What trademark classes does Lexli International, Inc. file in?
Lexli International, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Lexli International, Inc.'s most well-known trademarks?
Lexli International, Inc.'s registered trademark portfolio includes well-known marks such as LEXLI and ALOEGLYC. These are among 2 currently registered trademarks in the portfolio.
What is Lexli International, Inc.'s trademark registration success rate?
Lexli International, Inc. has a 67% trademark registration rate, with 2 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.